Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials

References

• WHO, Requirements for varicella vaccine (live). WHO Technical Report Series 1994;848:22-52
   Google Scholar
• Fairley CK, Miller E. Varicella-zoster virus epidemiology–a changing scene? J Infect Dis 1996;174:314
   PubMed Web of Science ®Google Scholar
• Vazquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001;344:955-60
   PubMed Web of Science ®Google Scholar
• Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005;352:450-8
   PubMed Web of Science ®Google Scholar
• Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA 2005;294:797-802
   PubMed Web of Science ®Google Scholar
• American academy of pediatrics. committee on infectious diseases Varicella vaccine update. Pediatrics 2000;105:1:136-41
   PubMed Web of Science ®Google Scholar
• Vaccine information statements-chickenpox. centers for disease control and prevention. 2008. (cited 30 June 2014) Available from: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/varicella.html
   Google Scholar
• Lieberman JM, Williams WR, Miller JM, et al. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J 2006;25(7):615-22
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis E, Baxter R, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics 2012;129:809-14
   PubMed Web of Science ®Google Scholar
• Watson BM, Laufer DS, Kuter BJ, et al. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. J Infect Dis 1996;173:731-4
   PubMed Web of Science ®Google Scholar
• White CJ, Stinson D, Staehle B, et al. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group. Clin Infect Dis 1997;24(5):925-31
   PubMed Web of Science ®Google Scholar
• Nolan T, McIntyre P, Roberton D, et al. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002;21:281-9
   PubMed Web of Science ®Google Scholar
• Shinefield H, Williams WR, et al. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J 2005;24:670-5
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J 2005;24:665-9
   PubMed Web of Science ®Google Scholar
• Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 2006;25:12-18
   PubMed Web of Science ®Google Scholar
• Lieberman JM, Williams WR, Miller JM, et al. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J 2006;25:615-22
   PubMed Web of Science ®Google Scholar
• Goh P, Lim FS, Han HH, et al. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection 2007;35:326-33
   PubMed Web of Science ®Google Scholar
• Schuster V, Otto W, Maurer L, et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J 2008;27:724-30
   PubMed Web of Science ®Google Scholar
• Cha S-H, Shin S-H, Lee T-J, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children. Clin Exp Vaccine research 2014;3(1):91-9
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. Version 5.1.0. Updated March 2011. Available from: http://handbook.cochrane.org/
   Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928
   PubMed Web of Science ®Google Scholar
• Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63(8):e1-e37
   PubMed Web of Science ®Google Scholar
• Review Manager (RevMan) (Computer program) version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. 2014
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
   PubMed Web of Science ®Google Scholar
• Brunell PA, Novelli VM, Lipton SV, et al. Combination vaccine against measles, mumps, rubella, and varicella. Pediatrics 1988;81:779-84
   PubMed Web of Science ®Google Scholar
• Brady MT, Bernstein HH, Byington CL, et al. Committee on Infectious Diseases. Policy statement: prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics 2011;128(3):630-2
   PubMed Web of Science ®Google Scholar
• Macartney KK, Gidding HF, Trinh L, et al. Febrile seizures following measles and varicella vaccines in young children in Australia. Vaccine 2014;33(11):1412-17
   PubMed Web of Science ®Google Scholar
• Schink T, Holstiege J, Kowalzik F, et al. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine 2014;32(6):645-50
   PubMed Web of Science ®Google Scholar
• O’Leary ST, Suh CA, Marin M, et al. Febrile seizures and measles-mumps-rubella-varicella (MMRV) vaccine: what do primary care physicians think? Vaccine 2012;30(48):6731-3
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis E, Fireman B, et al. Safety of measles-containing vaccines in 1-year-old children. Pediatrics 2015;135(2):e321-9
   PubMed Web of Science ®Google Scholar
• Zhou F, Ortega-Sanchez IR, Guris D, et al. An economic analysis of the universal varicella vaccination program in the United States. J Infect Dis 2008;197:S156-64
   PubMed Web of Science ®Google Scholar
• Valentim J, Sartori AM, de Soárez PC, et al. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine 2008;26:6281-91
   PubMed Web of Science ®Google Scholar